Research peptides

KLOW Peptide Dosage: Vial Chart, Composition and Evidence

KLOW peptide dosage: the 80 mg vial split, reconstitution and titration range reported by dosing sites, an injection-units chart, and what the evidence shows.

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published September 27, 2026Updated October 3, 2026

The short version

KLOW is a vendor-mixed vial of four research peptides - GHK-Cu, BPC-157, TB-500 and KPV - sold as one product rather than four. No study, human or animal, has tested the four combined. Each ingredient has its own separate evidence base. This page covers what vendors say is in the vial, what that evidence shows, KLOW's legal status, and the dosing figures circulating online. No regulator or clinical trial has established any of them.

KLOW is a vendor-picked mix of four peptides, not a studied combination product.
No human or animal study has tested GHK-Cu, BPC-157, TB-500 and KPV combined.
Two of its four ingredients are prohibited in sport at all times.
The dosing numbers below come from vendor and protocol sites, not a trial or regulator.

KLOW is a vendor-picked mixture of four peptides - GHK-Cu, BPC-157, TB-500 and KPV - sold together in a single vial. Each ingredient has its own research interest. GHK-Cu has been studied in skin and wound healing, BPC-157 and TB-500 in animal tissue-repair studies, and KPV in mouse models of gut inflammation. I found no study, of any kind, that has tested the mixture.

This page covers what vendors say is in the vial, what the separate published evidence on each ingredient shows, KLOW’s legal status, and the dosing figures circulating online. No trial or regulator has established any of those figures.

What’s actually in the vial

Two research-chemical vendors selling KLOW list the same per-ingredient breakdown: BioLongevity Labs and LiveWell Peptides. A third, True Research Labs, sells the same four ingredients in an 80 mg vial but does not publish a per-ingredient split on its product page.

Ingredient	Amount	Share of vial
GHK-Cu	50 mg	62.5%
BPC-157	10 mg	12.5%
TB-500	10 mg	12.5%
KPV	10 mg	12.5%
Total	80 mg	100%

All three describe it as a lyophilized (freeze-dried) powder in one vial, not four separately dosed peptides. All three carry near-identical disclaimers. LiveWell’s listing states the product is “FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION.” True Research Labs’ page says the same in different words: “not intended for human or animal consumption under any circumstances.”

Nobody selling KLOW represents it as a medicine, a supplement, or a reviewed product.

No study has tested the four combined

I could not locate a published human or animal study of GHK-Cu, BPC-157, TB-500 and KPV given together, at any dose, by any route. The closest published data point combines only two of the four. A rat Achilles tendon study Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below gave 32 rats BPC-157 alone, TB-500 alone, or both together. The doses were 10 mcg/kg/day BPC-157 and 60 mcg/kg/day TB-500, intraperitoneally, for four weeks. The combined arm did not outperform TB-500 alone on biomechanical strength or histopathology. The paper reports no added benefit from combining the two.

What the evidence says about each ingredient

Each component has its own, separate literature. Putting four peptides in one vial does not merge their evidence.

GHK-Cu is the majority of the vial by weight (62.5%). My copper peptides guide covers it in full. It is a legal cosmetic ingredient with decades of use and a real research history in wound healing. The human evidence for the bigger anti-ageing claims is limited, and a randomized human trial of topical GHK-Cu indexed in PubMed was negative on its objective endpoints.
BPC-157 has a large, consistently positive animal literature on tissue healing, covered in my BPC-157 guide. The human evidence is small. No BPC-157 study is indexed in PubMed as a clinical trial. The published human experience totals roughly 80 people across five small studies, and the only randomized placebo-controlled one was never published beyond a meeting abstract.
TB-500: my TB-500 guide reports that I could not locate a single completed, published human randomized trial, for any indication. Much of the tissue-repair literature people cite for it studied full-length thymosin beta-4, a different molecule. A recent rat tendon study using TB-500 by name was positive.
KPV: my KPV guide covers FDA’s own July 2026 review, which found zero human studies of KPV, by any route. The one animal data point is a 2008 mouse colitis study Dalmasso 2008 - Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78., in the references below. It added KPV to drinking water and reported reduced intestinal inflammation. The published abstract does not state an exact concentration, so neither does this page.

Legal status

KLOW’s status is mixed because it is a mix:

GHK-Cu is a legal cosmetic ingredient in the US and Australia - see the copper peptides guide for detail.
BPC-157 is not FDA-approved, sold as a research chemical, and prohibited at all times in sport under WADA’s Non-Approved Substances category - see the BPC-157 guide.
TB-500 is not FDA-approved, sold as a research chemical, and prohibited at all times in sport as a thymosin beta-4 derivative - see the TB-500 guide.
KPV is not FDA-approved and not on FDA’s 503A Bulks List, so no pharmacy can lawfully compound it - see the KPV guide.

Every vendor selling the combined vial states it is not for human or animal use. That includes True Research Labs, BioLongevity Labs and LiveWell Peptides. That is a research-chemical-industry disclaimer, not a legal opinion about what buyers do with the product.

The vendors I check that sell KLOW, with dated prices and the split on each label: where to buy KLOW.

KLOW dosage chart: what’s circulating, not what’s established

No study or regulator has established a KLOW dose, because nobody has published a trial of the four-peptide combination. Three dosing sites agree on the vial and reconstitution: Peptide Dosing Protocols, theklowpeptide.com and DosagePeptide.com. Each describes an 80 mg vial (50 mg GHK-Cu, 10 mg each of BPC-157, TB-500 and KPV) reconstituted with 3.0 mL of bacteriostatic water. That gives about 26.7 mg/mL of total blend. None of this is a research finding, and none of it is a recommendation from this site.

The three sites disagree on the week-by-week schedule:

DosagePeptide.com: a fixed 10-unit (~2.67 mg) dose with rising frequency.
theklowpeptide.com: a 10/15/20-unit weekly step-up.
Peptide Dosing Protocols: a 7.5/15/22.5-unit taper.

They agree on the overall range. Daily dosing rises from roughly 2 mg up to roughly 5-6 mg of total blend over the first several weeks of a cycle. The chart below gives the units for that vial across that range. None of the three sites is a clinical or regulatory source.

KLOW (GHK-Cu/BPC-157/TB-500/KPV) 80 mg vial

Water added	Concentration	1 unit =	2 mg	4 mg	6 mg
3 mL water	26.67 mg/mL	266.67 mcg	7.5 units	15 units	22.5 units

Units on a U-100 insulin syringe (100 units = 1 mL), to the nearest half unit. 2-6 mg spans the daily titration range described by three independent dosing sites; the exact week-by-week schedule differs by site.

Peptide Dosing Protocols describes a typical cycle of “4-6 weeks on, 2-4 weeks off,” with a note that it found “no safety data supports continuous use beyond 12 weeks.”

Reconstitution and injection volume

The chart above gives units for the specific 80 mg / 3.0 mL preparation that three dosing sites describe. For any other vial size or dilution, use the dosage calculator. It works out concentration and draw volume. It performs the math; it does not tell you what amount to target.

Who should not use it

No FDA-reviewed contraindication list exists for KLOW, or for BPC-157, TB-500 or KPV individually, because none of the three has gone through that review. There is no human safety data on the ingredients combined, and thin-to-zero human data on them separately (see above). Anyone pregnant, breastfeeding, immunocompromised, on other medications, or with a diagnosed medical condition has no regulator-reviewed information to weigh a decision against.

Risks

A four-peptide vial carries risks specific to blending, beyond each ingredient’s own risks:

No vendor-published third-party testing confirms the finished mixture contains all four components at the labeled ratio.
An injection-site or systemic reaction could come from any one ingredient or an interaction between them, with no way to isolate which.
FDA has separately flagged possible immunogenicity concerns and unresolved impurity questions for compounds in this class.

Material sold as KLOW is a research chemical with no regulator-verified purity, identity or concentration.

Common questions

What is KLOW?

KLOW is a vendor name for a lyophilized powder blend of four peptides in one vial: GHK-Cu, BPC-157, TB-500 and KPV. The most common split is 50 mg, 10 mg, 10 mg and 10 mg respectively, for 80 mg total. Multiple research-chemical vendors sell it as research-use-only material, not as a product approved or reviewed for human use.

What is the KLOW peptide dosage?

There is no established human dose, because no study of the four-peptide combination exists. Three dosing sites independently describe the same 80 mg vial in 3.0 mL bacteriostatic water. They titrate from roughly 2 mg up to roughly 5-6 mg of total blend per day over several weeks, though the week-by-week schedule differs by site. The dosage chart below gives the units for that vial across that range. These are not clinical findings and not a recommendation.

Has KLOW been tested in any study?

No. I could not find a published human or animal study of GHK-Cu, BPC-157, TB-500 and KPV combined. The closest published data point is a rat tendon study that combined two of the four ingredients, BPC-157 and TB-500. The combination performed no better than either one alone.

Is KLOW legal?

KLOW's status is mixed because it is a mix. GHK-Cu is a legal cosmetic ingredient in the US and Australia. BPC-157, TB-500 and KPV are not FDA-approved and are sold as research chemicals, not legally marketed for human use. Every vendor selling the combined vial states it is for laboratory research only, not for human or animal consumption.

Is KLOW banned in sports?

Two of its four ingredients are. BPC-157 is prohibited at all times under WADA's Non-Approved Substances category, and TB-500 is prohibited at all times as a thymosin beta-4 derivative. GHK-Cu and KPV do not appear on the WADA list.

What are the risks of KLOW?

A four-peptide vial adds risks specific to blending, on top of the risks of each ingredient. No vendor-published testing confirms the finished mixture at the stated ratio. Injection-site reactions could come from any one component or their interaction. Nothing about combining them has been studied for safety. FDA has separately flagged immunogenicity and impurity concerns for compounds in this class.

Who should not use KLOW?

No FDA-reviewed contraindication list exists for KLOW or for three of its four ingredients individually. There is no human safety data on the combination. Anyone pregnant, breastfeeding, immunocompromised, on other medications, or with a diagnosed medical condition has no regulator-reviewed information to weigh a decision against.

What are the side effects of taking KLOW peptide?

They are unknown for the blend itself. I found no study of the four combined, in any species. Each ingredient has its own thin safety record, covered on its own page. A reaction at the injection site or elsewhere could come from any of the four, with no way to tell which. FDA has also flagged immunogenicity and impurity concerns for compounds in this class.

References (8 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1.Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837.StudyPMID 42542926
2.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78.StudyPMID 18061177full text
3.True Research Labs - KLOW Blend product page, listing KPV, BPC-157, TB-500 and GHK-Cu and stating the product is for laboratory research use only, not for human or animal consumption.- True Research Labsother
4.BioLongevity Labs - KLOW Blend product page, stating 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV per 80 mg vial, research use only.- BioLongevity Labsother
5.LiveWell Peptides - KLOW product page, stating the same 50/10/10/10 mg composition and strictly-not-for-human-use terms.- LiveWell Peptides LLCother
6.Peptide Dosing Protocols - KLOW stack page, a circulating community protocol with reconstitution and titration figures, not a clinical or regulatory source.- peptidedosingprotocols.comother
7.theklowpeptide.com - KLOW Peptide Dosing page, independently stating the same 80 mg vial in 3.0 mL water and a titration up to 20 units (about 5.3 mg).- theklowpeptide.comother
8.America's Poison Centers - home page, confirming the national Poison Control number 1-800-222-1222.- America's Poison Centersother